Fresenius Medical Care AG reports Q1 results on May 5 with options traders leaning more defensively than usual — even as the short side of the trade has quietly retreated over the past month.
The clearest signal heading into earnings is in the options market. The put/call ratio has climbed to 1.86, running well above its 20-day average of 1.48. That is not yet at panic levels — the 52-week high touched 2.68 — but it marks a meaningful shift from mid-April, when the PCR was sitting closer to 1.10. Demand for downside protection has picked up sharply in the final two weeks before the print.
Short interest tells a notably different story. Bears have been covering, not adding. Estimated short interest has dropped roughly 16% over the past month to about 1.55 million shares, with the pace of covering accelerating through late April. At 3.34 days-to-cover and a borrow cost around 4%, the lending market carries no squeeze pressure — availability is ample and conditions are relaxed. The ORTEX short score of 34.5 ranks in just the 5th percentile of the short-interest universe, confirming this is not a heavily contested short.
Where the setup becomes more nuanced is in the earnings history. The last quarterly print — February 24 — hit the stock hard, dropping nearly 8% on the day and extending to an additional 5% loss over the following week. That reaction appears to have shaped the current defensive options posture, even as short sellers themselves have retreated. The cost to borrow has also risen sharply on a weekly basis, up 30% in the past week to 4.02% — though it remains well below the March highs near 6.8%, which suggests some incremental borrow demand without a structural squeeze.
On the fundamental side, valuation looks compressed. The stock trades at a P/E of 6.3 and an EV/EBITDA of 4.3 — the latter barely budged over the past 30 days. The price-to-book ratio has slid to 0.48, down sharply over the month. Analyst data is too dated to carry weight — the most recent rating change of note was a UBS downgrade to Sell in September 2025, and the consensus mean target on file is stale by several years. What is observable is that EPS surprise ranks in the 72nd percentile and EPS momentum over 30 days scores in the 62nd percentile, suggesting the company has recently been delivering ahead of depressed expectations.
Overall, positioning looks cautious rather than crowded: options traders have stacked puts into the print, but short sellers have been stepping back — making the May 5 report less a test of short conviction and more a question of whether FMS can avoid another sharp earnings-day disappointment at a valuation that already prices in considerable pessimism.
See the live data behind this article on ORTEX.
Open FMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
